Raquel Perry

Raquel Perry

Auto-generated profile, based on publicly available information

Raquel Perry

Department of Emergency Medicine, University of Utah, Salt Lake City, Utah, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2024 in Cancer Cytopathology
Verified
Journal Article
Closed access
RPRaquel A. Perry
Raquel A. Perry
MLMegan F. Lee
Megan F. Lee
RJRachel C. Jug
Rachel C. Jug
RDRajesh C. Dash
Rajesh C. Dash
DRDaniel J. Rocke
Daniel J. Rocke
XJXiaoyin “Sara” Jiang
Xiaoyin “Sara” Jiang

26 October 2023 in Ear, Nose & Throat Journal
Verified
Journal Article
Open access
JCJulia Canick
Julia Canick
DMDehra McGuire
Dehra McGuire
KKKayla W. Kilpatrick
Kayla W. Kilpatrick
RPRaquel Perry
Raquel Perry
MKMaragatha Kuchibhatla
Maragatha Kuchibhatla
JLJanet W. Lee
Janet W. Lee
Objective: Videofluoroscopic swallow studies (VFSS) are highly effective in characterizing pediatric dysphagia, but they are time- and resource-intensive, and necessitate the use of radiation. Identifying patients unlikely to benefit from VFSS is crucial to improving patient safety and resource allocation. The purpose of this study was to assess whether the ability of a patient to consume at least 0.5 oz by mouth is a reliable indicator of their ability to produce a diagnostically useful VFSS. Study Design: Retrospective chart review. Methods: Clinical data of pediatric patients aged 0 to 18 years, who underwent VFSS at a tertiary academic medical center from 2014 to 2021 were analyzed. Results: Regardless of whether due to mechanical dysphagia or oral aversion, an inability to consume at least 0.5 oz of any texture by mouth at home was not found to be associated with nondiagnostic VFSS. Age was found to have an effect on VFSS utility with toddlers having higher odds of nondiagnostic VFSS compared to children and adolescents. Overall, there was no significant interaction between the ability to take at least 0.5 oz and age group. Gastrointestinal (GI) and neuromuscular comorbidities were also associated with clinically useful swallow studies. Conclusions and Relevance: Clinicians should consider several factors, including age, at-home intake by mouth, and comorbidities such as neuromuscular and GI disorders, as they decide whether to order a VFSS.

17 April 2025 in Research Square
Verified
Preprint
Open access
PDF file
RVRaphael Valdivia
Raphael Valdivia
MPMaria Emilia Panzetta
Maria Emilia Panzetta
KMKatherine Mueller
Katherine Mueller
JAJason Arnold
Jason Arnold
RPRaquel Perry
Raquel Perry
RBRichard Bedlack
Richard Bedlack
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease that can progress at varying rates; however, the factors influencing progression rates in ALS patients remain unknown. In this study, we report distinct microbiome and metabolomic signatures associated with ALS progression rates. Rapid progression rates were transferable to a genetic mouse model of ALS following a fecal microbiota transplant (FMT) from patients exhibiting rapid disease progression. By focusing on microbial and metabolic markers shared between the FMT donors and mouse recipients, we identified Phocaeicola vulgatus as a microbial biomarker for slow progression. Additionally, we found strain-level differences in P. vulgatus among ALS patients and isolated a strain that partially alleviated disease in mice that received microbiota linked with rapid progression. Identifying microbiota that accelerates ALS progression, along with strains of P. vulgatus and correlated metabolites that mitigate such accelerated diseases, reveals new avenues for potential therapeutic interventions.

24 July 2025 in JACEP Open
Verified
Journal Article
Open access
RPRaquel Perry
Raquel Perry
WMWilliam Mehring
William Mehring
BJBenjamin Johnson
Benjamin Johnson
TBTimothy Batchelor
Timothy Batchelor
CHChristy Hill
Christy Hill
VLViveta Lobo
Viveta Lobo